Physician profile
Prathap Kumar Simhadri
NPI 1548410574
$8,479.89
in general payments reported to CMS, 2019-2025
28 companies · $2,612 in 2025
The $2,612 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $368 · 2021: $1,257 · 2022: $1,003 · 2023: $718 · 2024: $2,199 · 2025: $2,612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,768 · Travel and Lodging: $1,731 · Education: $29.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,768.03 |
| Travel and Lodging | $1,730.85 |
| Education | $29.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $2,636.08 | 2023-2025 | Filspari |
| E.R. Squibb & Sons, L.L.C. | $1,566.97 | 2019-2024 | Eliquis |
| Amgen INC. | $657.17 | 2022-2025 | Krystexxa, Tavneos |
| Astrazeneca Pharmaceuticals LP | $625.28 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $463.64 | 2022-2025 | Acthar, Terlivaz |
| Pfizer INC. | $335.80 | 2019-2024 | |
| Baxter Healthcare | $307.64 | 2021-2024 | |
| Calliditas Therapeutics US INC. | $283.34 | 2022-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $282.50 | 2019-2023 | Krystexxa |
| Vifor Pharma, INC. | $216.41 | 2023-2025 | Veltassa |
| Renalytix Ai, INC. | $215.16 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Otsuka America Pharmaceutical, INC. | $130.00 | 2021-2024 | Jynarque |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $125.35 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.30 | 2023-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $108.78 | 2019-2023 | Xarelto |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $89.05 | 2025 | |
| Ardelyx, INC. | $54.91 | 2024-2025 | Ibsrela |
| Kestra Medical Technology Services, INC. | $42.30 | 2023 | Assure Wcd |
| Bayer Healthcare Pharmaceuticals INC. | $39.95 | 2024 | |
| Fresenius USA Marketing, INC. | $34.85 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.75 | 2025 | Lifevest |
| Novo Nordisk INC | $21.47 | 2025 | Ozempic |
| Nxstage Medical, INC. | $21.36 | 2022 | |
| Cormedix INC. | $18.57 | 2024 | Defencath |
| Genzyme Corporation | $18.11 | 2024 | |
| Aurinia Pharma U.S., INC. | $17.81 | 2023 | Lupkynis |
| Opko Pharmaceuticals, LLC | $14.09 | 2025 | Rayaldee |
| Allergan, INC. | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prathap Kumar Simhadri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.